Arcutis Biotherapeutics (ARQT) FDA Announcement summary

Introduction and purpose

• FDA approved ZORYVE (roflumilast) cream 0.15% for mild to moderate atopic dermatitis in patients aged 6 and older, marking its third indication in under 24 months and expanding its label and addressable market.

• The launch aims to address significant unmet needs in atopic dermatitis, a chronic, burdensome skin disease affecting both children and adults.

• The product is positioned as a steroid-free, once-daily topical with broad insurance coverage and a focus on patient adherence.

• Announced a new co-promotion agreement with Kowa Pharmaceuticals to reach patients outside dermatology offices, including primary care and pediatric markets.

• Emphasized the company's vision to build a leading innovation-driven dermatology franchise.

Details of approval or decision

• FDA approved ZORYVE Cream 0.15% for once-daily use in mild to moderate atopic dermatitis for patients 6 years and older, with no limitations on treatment area, body surface, or duration.

• ZORYVE is now approved for three major inflammatory skin diseases: atopic dermatitis, plaque psoriasis, and seborrheic dermatitis.

• The label expansion increases the addressable market by 1.4 million patients and more than triples the total addressable market to 4.4 million commercially covered patients.

• Kowa will use its primary care sales force to promote ZORYVE for all FDA-approved indications to primary care practitioners and pediatricians, while Arcutis retains responsibility for dermatology specialists.

Impact on industry and stakeholders

• The Kowa partnership enables access to millions of patients treated outside dermatology clinics, including those with Medicare and Medicaid, and expands the total addressable market.

• Early PBM coverage and anticipated rapid downstream insurance coverage are expected to accelerate market access and reduce gross-to-net ratios.

• Sustained revenue growth and operational leverage are expected with new indications and expanded prescriber base.

• Kowa's established relationships in primary care are anticipated to enhance patient access and support.